We found when limiting the analysis to platinum-sensitive patients, those re-treated with platinum–based chemotherapy had a longer numerical survival than those switched to treatment with topotecan single agent for both extensive and limited stage, but did not reach statistical significance, similar to a previously published study [ 31 ].
← all excerpts
Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes.
1
—
—